Neurocrine (NBIX) Catches Eye: Stock Jumps 6.5%
Neurocrine Biosciences, Inc. NBIX was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $86.13 –$115.83 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen four negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Neurocrine currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Neurocrine Biosciences, Inc. Price
Neurocrine Biosciences, Inc. Price | Neurocrine Biosciences, Inc. Quote
Investors interested in the Medical - Drugs industry may consider Eisai Co., Ltd. ESALY, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is NBIX going up? Or down? Predict to see what others think:Up or Down
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report
Eisai Co. (ESALY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
